Phaseline

Targets › CD96

CD96 (T-cell surface protein tactile): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2029.

May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. (UniProt, P40200)

Open in Phaseline: the race on CD96, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of ChicagoVolrustomig
CD96 antagonist monoclonal antibody
CD96Phase 2Head and Neck CancerAug 2029

Conditions

Head and Neck Cancer (1)

Modalities

mixed (1)

Companies

University of Chicago (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.